Analysis of management and treatment effects of pulmonary tuberculosis patients in Nanshan District, Shenzhen City, 2011—2020

doi:10.19983/j.issn.2096-8493.20220098

Abstract

Abstract:

Objective: To evaluate the management and treatment effects of pulmonary tuberculosis (PTB) patients registered for treatment in Nanshan District, Shenzhen City, from 2011 to 2020, and to provide a basis for optimizing prevention and control measures in the future. Methods: Information of registration, treatment management and outcomes of PTB patients in Nanshan District from 2011 to 2020 was collected from the Chinese Disease Prevention and Control Information System, and statistical analysis of management and treatment indicators was performed using the descriptive analysis method. Results: From 2011 to 2020, a total of 5386 PTB cases were registered and managed in Nanshan District, with an average annual registration rate of 40.26/100000 (5386/13379013) which were statistically significantly differentiated among years ( $χ t r e n d 2$ =31.160, P<0.001); the registration rates for local and migrated populations were 12.80/100000 (994/7767261) and 78.26/100000 (4392/5611752) respectively, the latter was significantly higher than the former (χ²=25.623, P=0.002).The pathogenetically positive rate among all cases was 53.89% (2785/5168) during the 10-year period, while the rate was significantly higher in 2016-2020 (58.08%,1646/2834) than in 2011-2015 (48.80%,1139/2334) with a statistically significant difference (χ²=44.359,P<0.001). 85.04% (1194/1404) of smear-positive cases registered in 2011-2020 got sputum negative conversion after being treated for 2 months, while retreated smear-positive cases got a lower 2-months conversion rate (76.00%, 95/125) than new smear-positive patients (85.93%, 1099/1279)(χ²=8.821, P=0.003); the average treatment success rate was 91.66% (4780/5215) over the 10 years which was higher in local population (94.90%, 911/960) than in migrated population (90.93%, 3869/4255), with a statistically significant difference (χ²=16.127,P<0.001). Conclusion: The PTB registration rate in Nanshan District from 2011 to 2020 showed an overall decreasing trend, a significant increase in the pathogenetically positive rate, a treatment success rate of more than 90%, and a significant positive PTB management and control effect.

Key words: Tuberculosis, pulmonary/prevention and control, Patient care management, Treatment outcome, Shenzhen city

CLC Number:

R521

Huang Yao, Fan Yuzheng, Wang Xiangyu, Zhong Tao, Zhang Jie, Yang Nansen, Li Shengbin, Ye Xuetian, Liu Shengyuan. Analysis of management and treatment effects of pulmonary tuberculosis patients in Nanshan District, Shenzhen City, 2011—2020[J]. Journal of Tuberculosis and Lung Disease , 2022, 3(6): 463-468. doi: 10.19983/j.issn.2096-8493.20220098

Figures/Tables 4

References 24

[1]	GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories,1990—2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet,2020, 396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9. doi: 10.1016/S0140-6736(20)30925-9 URL
[2]	张黎明. 结核病分级诊疗和综合防治服务模式在结核病防治中的效果探讨. 智慧健康, 2021, 7(13):29-31. doi:10.19335/j.cnki.2096-1219.2021.13.009. doi: 10.19335/j.cnki.2096-1219.2021.13.009 URL
[3]	Jeremiah C, Petersen E, Nantanda R, et al. The WHO Global Tuberculosis 2021 Report-not so good news and turning the tide back to End TB.Int J Infect Dis, 2022:S1201- 9712(22)00149-7. doi:10.1016/j.ijid.2022.03.011. doi: 10.1016/j.ijid.2022.03.011 URL
[4]	中华人民共和国国家卫生和计划生育委员会. WS 196—2017 结核病分类. 2017-11-09.
[5]	中华人民共和国国家卫生健康委员会办公厅. 中国结核病预防控制工作技术规范(2020年版).国卫办疾控函〔2020〕279号. 2020-04-02.
[6]	钟涛, 赵锦, 王健, 等. 深圳市南山区2001—2010年登记的活动性肺结核病人管理与治疗效果分析. 中国社会医学杂志, 2013, 30(2):133-135. doi:10.3969/j.issn.1673-5625.2013.02.023. doi: 10.3969/j.issn.1673-5625.2013.02.023 URL
[7]	陈蕊明, 彭东东, 纪丽微, 等. 2011—2015年广东省汕头市结核病流行病学特征及DOTS策略评价. 实用预防医学, 2017, 24(5):602-604. doi:10.3969/j.issn.1006-3110.2017.05.026. doi: 10.3969/j.issn.1006-3110.2017.05.026 URL
[8]	深圳市卫生和计划生育委员会. 深圳市肺结核病归口管治办法.2014-04-30.
[9]	中华人民共和国国家卫生和计划生育委员会办公厅. 国家卫生计生委办公厅关于开展结核病分级诊疗和综合防治服务模式试点工作的通知.国卫办疾控函〔2016〕672号. 2016-06-24.
[10]	端木宏谨, 王黎霞. 中国结核病控制的可持续发展问题的探讨. 中国防痨杂志, 1999, 21(2):7-8.
[11]	Fei H, Yinyin X, Hui C, et al. The impact of the COVID-19 epidemic on tuberculosis control in China. Lancet Reg Health West Pac, 2020, 3:100032. doi:10.1016/j.lanwpc.2020.100032. doi: 10.1016/j.lanwpc.2020.100032 URL
[12]	马剑平, 钟涛, 郭旭君, 等. 深圳市南山区结核病分级诊疗实践与探索. 中国医院管理, 2020, 40(7):92-93.
[13]	严新凤, 秦玉宝, 陈智聪, 等. 深圳市龙华新区流动人口肺结核患者来源分析. 中国防痨杂志, 2015, 37(9):987-991. doi:10.3969/j.issn.1000-6621.2015.09.016. doi: 10.3969/j.issn.1000-6621.2015.09.016 URL
[14]	钟涛, 刘盛元, 詹广兴, 等. 2005—2016年深圳市南山区肺结核流行特征分析. 疾病监测, 2018, 33(9):724-727. doi:10.3784/j.issn.1003-9961.2018.09.006. doi: 10.3784/j.issn.1003-9961.2018.09.006 URL
[15]	徐光明, 叶小红, 张震, 等. 2009—2018年临海市肺结核流行特征. 预防医学, 2021, 33(1):49-51. doi:10.19485/j.cnki.issn2096-5087.2021.01.011. doi: 10.19485/j.cnki.issn2096-5087.2021.01.011 URL
[16]	中华人民共和国卫生部, 中华人民共和国教育部. 关于印发《学校结核病防控工作规范(试行)》的通知. 卫办疾控发〔2010〕133号. 2010-07-01.
[17]	国家卫生计生委办公厅, 教育部办公厅. 学校结核病防控工作规范(2017版).国卫办疾控函〔2017〕22号. 2017-06-26.
[18]	张洁, 樊惠霞, 张海燕, 等. 初治涂阳肺结核治疗2个月末痰菌未转阴的影响因素研究. 宁夏医学杂志, 2016, 38(5): 433-436. doi:10.13621/j.1001-5949.2016.05.0433. doi: 10.13621/j.1001-5949.2016.05.0433 URL
[19]	王慧, 许婕, 陈可, 等. 2012—2017年扬州市结核病流行特征与患者治疗转归分析. 南通大学学报(医学版), 2019, 39(5): 394-396. doi:10.16424/j.cnki.cn32-1807/r.2019.05.016. doi: 10.16424/j.cnki.cn32-1807/r.2019.05.016 URL
[20]	梁爽, 韩东伟, 钟威, 等. 抗结核固定剂量复合制剂联合左氧氟沙星治疗复治涂阳肺结核患者的效果分析. 结核病与肺部健康杂志, 2019, 8(2):149-152. doi:10.3969/j.issn.2095-3755.2019.02.016. doi: 10.3969/j.issn.2095-3755.2019.02.016 URL
[21]	叶海明, 陈文思, 张菊芳, 等. 深圳市福田区结核病分级诊疗和综合防治服务模式试点工作效果分析. 中国防痨杂志, 2019, 41(8):900-904. doi:10.3969/j.issn.1000-6621.2019.08.018. doi: 10.3969/j.issn.1000-6621.2019.08.018 URL
[22]	张娟娟, 胡方祥, 王云霞, 等. 2011—2015年深圳市宝安区结核病控制项目效果评价. 职业与健康, 2018, 34(7):946-949,953.
[23]	黄学贵, 刘国琴, 郁艳艳, 等. 贵州省结核病防治影响因素研究. 现代预防医学, 2014, 41(16): 3033-3035,3041.
[24]	管红云, 谭卫国, 杨应周, 等. 基于深圳市电子网络督导管理系统的肺结核患者管理治疗情况分析. 中国防痨杂志, 2017, 39(7):702-707. doi:10.3969/j.issn.1000-6621.2017.07.007. doi: 10.3969/j.issn.1000-6621.2017.07.007 URL

年份	户籍人口			非户籍人口			合计
年份	登记例数	人口数	登记率 (/10万)	登记例数	人口数	登记率 (/10万)	登记例数	人口数	登记率 (/10万)
2011	86	549191	15.66	486	550722	88.25	572	1099913	52.00
2012	67	616048	10.88	418	492473	84.88	485	1108521	43.75
2013	48	671708	7.15	387	447377	86.50	435	1119085	38.87
2014	49	710260	6.90	398	425618	93.51	447	1135878	39.35
2015	55	755919	7.28	383	535233	71.56	438	1291152	33.92
2016	83	810194	10.24	414	546113	75.81	497	1356307	36.64
2017	131	894405	14.65	600	530156	113.17	731	1424561	51.31
2018	154	921557	16.71	459	572074	80.23	613	1493631	41.04
2019	146	980043	14.90	464	565745	82.02	610	1545788	39.46
2020	175	857936	20.40	383	946241	40.48	558	1804177	30.93
总计	994	7767261	12.80	4392	5611752	78.26	5386	13379013	40.26

年份	登记总例数	病原学阳性		病原学阴性		无病原学结果
		病原学阳性		病原学阴性		未痰检		结核性胸膜炎
		登记例数	构成比 (%)	登记例数	构成比 (%)	登记例数	构成比 (%)	登记例数	构成比 (%)
2011	572	283	49.48	288	50.35	0	0.00	1	0.17
2012	485	236	48.66	240	49.48	0	0.00	9	1.86
2013	435	221	50.80	209	48.05	0	0.00	5	1.15
2014	447	196	43.85	239	53.47	0	0.00	12	2.68
2015	438	203	46.35	219	50.00	0	0.00	16	3.65
2016	497	232	46.68	220	44.27	0	0.00	45	9.05
2017	731	390	53.35	298	40.77	11	1.50	32	4.38
2018	613	332	54.16	233	38.01	11	1.79	37	6.04
2019	610	367	60.16	210	34.43	8	1.31	25	4.10
2020	558	325	58.24	180	32.26	17	3.05	36	6.45
总计	5386	2785	51.71	2336	43.37	47	0.87	218	4.05

年龄组 (岁)	合计		户籍人口		非户籍人口
年龄组 (岁)	登记例数	构成比(%)	登记例数	构成比(%)	登记例数	构成比(%)
0~14	15	0.28	4	0.40	11	0.25
15~24	1411	26.20	191	19.22	1220	27.78
25~34	2110	39.18	364	36.62	1746	39.75
35~44	752	13.96	184	18.51	568	12.93
45~54	574	10.66	131	13.18	443	10.09
55~64	320	5.94	58	5.84	262	5.97
≥65	204	3.78	62	6.23	142	3.23
总计	5386	100.00	994	100.00	4392	100.00

年份	登记例数			治疗成功例数			诊断变更例数			转入耐多药治疗例数			治疗成功率(%)
年份	户籍人口	非户籍人口	全人口	户籍人口	非户籍人口	全人口	户籍人口	非户籍人口	全人口	户籍人口	非户籍人口	全人口	户籍人口	非户籍人口	全人口
2011	86	486	572	78	449	527	1	4	5	3	2	5	95.12	93.54	93.77
2012	67	418	485	64	366	430	1	1	2	0	7	7	96.97	89.27	90.34
2013	48	387	435	45	348	393	0	10	10	1	5	6	95.74	93.55	93.79
2014	49	398	447	45	343	388	0	10	10	0	8	8	91.84	90.26	90.44
2015	55	383	438	52	328	380	1	1	2	1	10	11	98.11	88.17	89.41
2016	83	414	497	73	349	422	3	5	8	2	9	11	93.59	87.25	88.28
2017	131	600	731	122	536	658	0	4	4	0	16	16	93.13	92.41	92.55
2018	154	459	613	139	399	538	2	10	12	7	7	14	95.86	90.27	91.65
2019	146	464	610	132	406	538	4	10	14	3	6	9	94.96	90.63	91.65
2020	175	383	558	161	345	506	3	7	10	2	5	7	94.71	92.99	93.53
总计	994	4392	5386	911	3869	4780	15	62	77	19	75	94	94.90	90.93	91.66